This segment of the discussion was focused on the current guidelines regarding the use of multi-gene assays and was aimed at eliciting the expert panel’s opinion on the optimal duration of adjuvant endocrine therapy for patients with hormone receptor-positive early breast cancer and, specifically, whether there is a clinically meaningful benefit of extending AI-based endocrine therapy to 10 years for selected patients. The gene discussed is NR4A1; the disease is breast cancer.